{"DataElement":{"publicId":"2685158","version":"2","preferredName":"Histiocytic and Dendritic Cell Neoplasms Classification Type","preferredDefinition":"A description of the histiocytic disorder classification.","longName":"HSTCTC_CLASS_TP","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"2685156","version":"1","preferredName":"Histiocytic and Dendritic Cell Neoplasms Classification","preferredDefinition":"Rare tumors that affect the hematopoietic and lymphoid tissues. The cells of origin are the histiocytes and accessory cells. They can occur at any age and show no significant variations in geographical distribution. This category includes the histiocytic sarcoma, Langerhans cell histiocytosis, Langerhans cell sarcoma, interdigitading dendritic cell sarcoma/tumor, follicular dendritic cell sarcoma/tumor, and dendritic cell sarcoma, not otherwise specified. (WHO, 2001)_A method of generalization, the systematic arrangement of entities into classes or groups based on mutual similarity and certain differing characteristics.","longName":"HSTCTC_CLASS","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"2685154","version":"1","preferredName":"Histiocytic and Dendritic Cell Neoplasms","preferredDefinition":"These are rare tumors that affect the hematopoietic and lymphoid tissues.  The cells of origin are the histiocytes and accessory cells. (WHO, 2001) -- 2003","longName":"C9294","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Histiocytic and Dendritic Cell Neoplasm","conceptCode":"C9294","definition":"A group of rare tumors that affect the hematopoietic and lymphoid tissues. The cells of origin are the histiocytes and accessory cells. This category includes the following: Langerhans cell histiocytosis, Langerhans cell sarcoma, indeterminate dendritic cell histiocytosis, interdigitating dendritic cell sarcoma, histiocytic sarcoma, disseminated juvenile xanthogranuloma, Erdheim-Chester disease, Rosai-Dorfman-Destombes disease, ALK-positive histiocytosis, and follicular dendritic cell sarcoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3B9695F0-3A57-052B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-03","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-03","modifiedBy":"ONEDATA","dateModified":"2007-10-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2321361","version":"1","preferredName":"Classification","preferredDefinition":"Classification; the grouping of things into classes or categories.","longName":"C25161","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Classification","conceptCode":"C25161","definition":"A method of generalization, the systematic arrangement of entities into classes or groups based on mutual similarity and certain differing characteristics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FCF89106-20AF-2D93-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-29","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-07-29","modifiedBy":"ONEDATA","dateModified":"2005-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3B9695F0-3A65-052B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-03","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-03","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":". Updated def. No version needed. AK 11/6/13","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2685142","version":"1.1","preferredName":"Histiocytic and Dendritic Cell Neoplasms Type","preferredDefinition":"Rare tumors that affect the hematopoietic and lymphoid tissues. The cells of origin are the histiocytes and accessory cells. They can occur at any age and show no significant variations in geographical distribution. This category includes the histiocytic sarcoma, Langerhans cell histiocytosis, Langerhans cell sarcoma, interdigitading dendritic cell sarcoma/tumor, follicular dendritic cell sarcoma/tumor, and dendritic cell sarcoma, not otherwise specified. (WHO, 2001)_Something distinguishable as an identifiable class based on common qualities.","longName":"HSTCTC_TP","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"60","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Familial Hemophagocytic Lymphohistiocytosis, Perforin deficiency (FHL2)","valueDescription":null,"ValueMeaning":{"publicId":"14679114","version":"1","preferredName":"Familial Hemophagocytic Lymphohistiocytosis Type 2","longName":"14679114v1.00","preferredDefinition":"Familial hemophagocytic lymphohistiocytosis caused by biallelic mutations in the PRF1 gene.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Familial Hemophagocytic Lymphohistiocytosis Type 2","conceptCode":"C203462","definition":"Familial hemophagocytic lymphohistiocytosis caused by biallelic mutations in the PRF1 gene.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F26BACC-B58F-1C21-E063-731AD00AD520","latestVersionIndicator":"Yes","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F26BACC-B595-1C21-E063-731AD00AD520","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"Familial Hemophagocytic Lymphohistiocytosis, UNC13D (FHL3)","valueDescription":null,"ValueMeaning":{"publicId":"14679115","version":"1","preferredName":"Familial Hemophagocytic Lymphohistiocytosis Type 3","longName":"14679115v1.00","preferredDefinition":"Familial hemophagocytic lymphohistiocytosis caused by biallelic mutations in the UNC13D gene.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Familial Hemophagocytic Lymphohistiocytosis Type 3","conceptCode":"C203463","definition":"Familial hemophagocytic lymphohistiocytosis caused by biallelic mutations in the UNC13D gene.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F26BACC-B590-1C21-E063-731AD00AD520","latestVersionIndicator":"Yes","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F26BACC-B596-1C21-E063-731AD00AD520","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"Familial Hemophagocytic Lymphohistiocytosis, STX11 (FHL4)","valueDescription":null,"ValueMeaning":{"publicId":"14679116","version":"1","preferredName":"Familial Hemophagocytic Lymphohistiocytosis Type 4","longName":"14679116v1.00","preferredDefinition":"Familial hemophagocytic lymphohistiocytosis caused by biallelic mutations in the STX11 gene.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Familial Hemophagocytic Lymphohistiocytosis Type 4","conceptCode":"C203461","definition":"Familial hemophagocytic lymphohistiocytosis caused by biallelic mutations in the STX11 gene.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F26BACC-B591-1C21-E063-731AD00AD520","latestVersionIndicator":"Yes","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F26BACC-B597-1C21-E063-731AD00AD520","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"Familial Hemophagocytic Lymphohistiocytosis, STXBP2 (FHL5)","valueDescription":null,"ValueMeaning":{"publicId":"14679117","version":"1","preferredName":"Familial Hemophagocytic Lymphohistiocytosis Type 5","longName":"14679117v1.00","preferredDefinition":"Familial hemophagocytic lymphohistiocytosis caused by biallelic mutations in the STXBP2 gene.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Familial Hemophagocytic Lymphohistiocytosis Type 5","conceptCode":"C203464","definition":"Familial hemophagocytic lymphohistiocytosis caused by biallelic mutations in the STXBP2 gene.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F26BACC-B592-1C21-E063-731AD00AD520","latestVersionIndicator":"Yes","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F26BACC-B598-1C21-E063-731AD00AD520","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"Familial Hemophagocytic Lymphohistiocytosis, no mutation identified","valueDescription":null,"ValueMeaning":{"publicId":"14679118","version":"1","preferredName":"Negation Mutation Abnormality Familial Hemophagocytic Lymphohistiocytosis","longName":"14679118v1.00","preferredDefinition":"An operation in which a term denies or inverts the meaning of another term or construction._Any transmissible change in the genetic material of an organism, which can result from radiation, viral infection, transposition, treatment with mutagenic chemicals and errors during DNA replication or meiosis. The effects of mutation range from single base changes to loss or gain of complete chromosomes. As many of the simpler alterations to DNA may be repaired, such changes are only heritable once the change is fixed in the DNA by the process of replication. Mutations may be associated with genetic diversity or with pathologies including cancer._A rare, life-threatening disorder usually appearing during the first few months of life. It is caused by abnormalities in the PRF1, UNC13D, and STX11 genes. It is characterized by histiocytic proliferation and phagocytosis. Patients present with fever, lymphadenopathy, and hepatosplenomegaly.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Negation","conceptCode":"C25594","definition":"An operation in which a term denies or inverts the meaning of another term or construction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Mutation Abnormality","conceptCode":"C45576","definition":"Any transmissible change in the genetic material of an organism, which can result from radiation, viral infection, transposition, treatment with mutagenic chemicals and errors during DNA replication or meiosis. The effects of mutation range from single base changes to loss or gain of complete chromosomes. As many of the simpler alterations to DNA may be repaired, such changes are only heritable once the change is fixed in the DNA by the process of replication. Mutations may be associated with genetic diversity or with pathologies including cancer.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Familial Hemophagocytic Lymphohistiocytosis","conceptCode":"C61276","definition":"A rare, life-threatening disorder usually appearing during the first few months of life. It is caused by abnormalities in the PRF1, UNC13D, and STX11 genes. It is characterized by histiocytic proliferation and phagocytosis. Patients present with fever, lymphadenopathy, and hepatosplenomegaly.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F26BACC-B593-1C21-E063-731AD00AD520","latestVersionIndicator":"Yes","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F26BACC-B599-1C21-E063-731AD00AD520","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"Familial Hemophagocytic Lymphohistiocytosis, other mutations","valueDescription":null,"ValueMeaning":{"publicId":"14679119","version":"1","preferredName":"Other Mutation Abnormality Familial Hemophagocytic Lymphohistiocytosis","longName":"14679119v1.00","preferredDefinition":"Different than the one(s) previously specified or mentioned._Any transmissible change in the genetic material of an organism, which can result from radiation, viral infection, transposition, treatment with mutagenic chemicals and errors during DNA replication or meiosis. The effects of mutation range from single base changes to loss or gain of complete chromosomes. As many of the simpler alterations to DNA may be repaired, such changes are only heritable once the change is fixed in the DNA by the process of replication. Mutations may be associated with genetic diversity or with pathologies including cancer._A rare, life-threatening disorder usually appearing during the first few months of life. It is caused by abnormalities in the PRF1, UNC13D, and STX11 genes. It is characterized by histiocytic proliferation and phagocytosis. Patients present with fever, lymphadenopathy, and hepatosplenomegaly.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Mutation Abnormality","conceptCode":"C45576","definition":"Any transmissible change in the genetic material of an organism, which can result from radiation, viral infection, transposition, treatment with mutagenic chemicals and errors during DNA replication or meiosis. The effects of mutation range from single base changes to loss or gain of complete chromosomes. As many of the simpler alterations to DNA may be repaired, such changes are only heritable once the change is fixed in the DNA by the process of replication. Mutations may be associated with genetic diversity or with pathologies including cancer.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Familial Hemophagocytic Lymphohistiocytosis","conceptCode":"C61276","definition":"A rare, life-threatening disorder usually appearing during the first few months of life. It is caused by abnormalities in the PRF1, UNC13D, and STX11 genes. It is characterized by histiocytic proliferation and phagocytosis. Patients present with fever, lymphadenopathy, and hepatosplenomegaly.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F26BACC-B594-1C21-E063-731AD00AD520","latestVersionIndicator":"Yes","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F26BACC-B59A-1C21-E063-731AD00AD520","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"Langerhans cell histiocytosis (histiocytosis-X)","valueDescription":null,"ValueMeaning":{"publicId":"2838588","version":"1","preferredName":"Langerhans Cell Histiocytosis","longName":"2838588","preferredDefinition":"A neoplastic proliferation of Langerhans cells which contain Birbeck granules by ultrastructural examination. Three major overlapping syndromes are recognized: eosinophilic granuloma, Letterer-Siwe disease, and Hand-Schuller-Christian disease. The clinical course is generally related to the number of organs affected at presentation. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Langerhans Cell Histiocytosis","conceptCode":"C3107","definition":"A neoplastic proliferation of Langerhans cells which contain Birbeck granules by ultrastructural examination. Three major overlapping syndromes are recognized: eosinophilic granuloma, Letterer-Siwe disease, and Hand-Schuller-Christian disease. The clinical course is generally related to the number of organs affected at presentation. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A5F1C9-F6D7-B082-E040-BB89AD436154","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"GDEEN","dateModified":"2023-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F26BACC-B59B-1C21-E063-731AD00AD520","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"Malignant histiocytosis","valueDescription":null,"ValueMeaning":{"publicId":"3377614","version":"1","preferredName":"Malignant Histiocytosis","longName":"3377614","preferredDefinition":"An antiquated term referring to cases of systemic non-Hodgkin lymphomas which are composed of large, atypical neoplastic lymphoid cells and cases of hemophagocytic syndromes. In the past, cases of anaplastic large cells lymphoma were called malignant histiocytosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Histiocytosis","conceptCode":"C7202","definition":"An antiquated term referring to cases of systemic non-Hodgkin lymphomas which are composed of large, atypical neoplastic lymphoid cells and cases of hemophagocytic syndromes. In the past, cases of anaplastic large cells lymphoma were called malignant histiocytosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B8EE9528-256D-ECE1-E040-BB89AD4354FD","latestVersionIndicator":"Yes","beginDate":"2012-02-14","endDate":null,"createdBy":"NYCHM","dateCreated":"2012-02-14","modifiedBy":"ONEDATA","dateModified":"2012-02-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F26BACC-B59D-1C21-E063-731AD00AD520","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"Other histiocytic disorder","valueDescription":null,"ValueMeaning":{"publicId":"2685145","version":"1","preferredName":"Other Histiocytic and Dendritic Cell Neoplasms","longName":"2685145","preferredDefinition":"Not otherwise specified.: These are rare tumors that affect the hematopoietic and lymphoid tissues.  The cells of origin are the histiocytes and accessory cells. (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Histiocytic and Dendritic Cell Neoplasm","conceptCode":"C9294","definition":"A group of rare tumors that affect the hematopoietic and lymphoid tissues. The cells of origin are the histiocytes and accessory cells. This category includes the following: Langerhans cell histiocytosis, Langerhans cell sarcoma, indeterminate dendritic cell histiocytosis, interdigitating dendritic cell sarcoma, histiocytic sarcoma, disseminated juvenile xanthogranuloma, Erdheim-Chester disease, Rosai-Dorfman-Destombes disease, ALK-positive histiocytosis, and follicular dendritic cell sarcoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3B95E7BE-A0D1-6434-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-03","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F26BACC-B59E-1C21-E063-731AD00AD520","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"Histiocytic disorder, not otherwise specified","valueDescription":null,"ValueMeaning":{"publicId":"2685144","version":"1","preferredName":"Not Otherwise Specified Histiocytic and Dendritic Cell Neoplasms","longName":"2685144","preferredDefinition":"Not characterized in any other way.: These are rare tumors that affect the hematopoietic and lymphoid tissues.  The cells of origin are the histiocytes and accessory cells. (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Otherwise Specified","conceptCode":"C19594","definition":"Not characterized in any other way.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Histiocytic and Dendritic Cell Neoplasm","conceptCode":"C9294","definition":"A group of rare tumors that affect the hematopoietic and lymphoid tissues. The cells of origin are the histiocytes and accessory cells. This category includes the following: Langerhans cell histiocytosis, Langerhans cell sarcoma, indeterminate dendritic cell histiocytosis, interdigitating dendritic cell sarcoma, histiocytic sarcoma, disseminated juvenile xanthogranuloma, Erdheim-Chester disease, Rosai-Dorfman-Destombes disease, ALK-positive histiocytosis, and follicular dendritic cell sarcoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3B95D884-4C97-60F8-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-03","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F26BACC-B59F-1C21-E063-731AD00AD520","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"Li-Fraumeni Syndrome","valueDescription":null,"ValueMeaning":{"publicId":"3211225","version":"1","preferredName":"Li-Fraumeni Syndrome","longName":"3211225","preferredDefinition":"An autosomal dominant hereditary neoplastic syndrome caused by an alteration in the p53 tumor suppressor gene.  It is characterized by the development of malignant neoplasms at various anatomic sites.  The malignant neoplasms associated with Li-Fraumeni syndrome include adrenal cortex carcinoma, astrocytic tumors, colorectal carcinoma, gastric carcinoma, malignant breast neoplasms, medulloblastoma, osteosarcoma, and soft tissue sarcomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Li-Fraumeni Syndrome","conceptCode":"C3476","definition":"An autosomal dominant cancer predisposition syndrome caused by germline mutations of the TP53 gene. It is associated with breast carcinoma, choroid plexus carcinoma, adrenal cortex carcinoma, astrocytic tumors, medulloblastoma, soft tissue sarcoma, osteosarcoma, and leukemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-DF6B-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"102F2C02-43EA-4FE9-E063-731AD00A87BA","beginDate":"2024-01-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-30","modifiedBy":"KUMMEROA","dateModified":"2024-01-30","deletedIndicator":"No"},{"value":"Hemophagocytosis","valueDescription":null,"ValueMeaning":{"publicId":"2579881","version":"1","preferredName":"hemophagocytosis","longName":"2579881","preferredDefinition":"The term hemophagocytosis describes the pathologic finding of activated macrophages, engulfing erythrocytes, leukocytes, platelets, and their precursor cells. (from Medscape: Hemophagocytic Syndromes and Infection)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hemophagocytosis","conceptCode":"C35985","definition":"The term hemophagocytosis describes the pathologic finding of activated macrophages, engulfing erythrocytes, leukocytes, platelets, and their precursor cells. (from Medscape: Hemophagocytic Syndromes and Infection)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0516-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-06-16","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2006-06-16","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"102FC644-3754-791B-E063-731AD00A73E4","beginDate":"2024-01-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-30","modifiedBy":"KUMMEROA","dateModified":"2024-01-30","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2685141","version":"1","preferredName":"Histiocytic and Dendritic Cell Neoplasms Type","preferredDefinition":"These are rare tumors that affect the hematopoietic and lymphoid tissues.  The cells of origin are the histiocytes and accessory cells. (WHO, 2001) -- 2003:Type; a subdivision of a particular kind of thing.","longName":"C9294:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Histiocytic and Dendritic Cell Neoplasm","conceptCode":"C9294","definition":"A group of rare tumors that affect the hematopoietic and lymphoid tissues. The cells of origin are the histiocytes and accessory cells. This category includes the following: Langerhans cell histiocytosis, Langerhans cell sarcoma, indeterminate dendritic cell histiocytosis, interdigitating dendritic cell sarcoma, histiocytic sarcoma, disseminated juvenile xanthogranuloma, Erdheim-Chester disease, Rosai-Dorfman-Destombes disease, ALK-positive histiocytosis, and follicular dendritic cell sarcoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3B966CA5-B57D-49EE-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-03","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-03","modifiedBy":"ONEDATA","dateModified":"2007-10-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"DRAFT MOD","registrationStatus":"Application","id":"0F269FA2-EB5B-178C-E063-731AD00A2F27","latestVersionIndicator":"Yes","beginDate":"2007-10-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-30","changeDescription":".Added 1 PV for 2400. AK 10/24/13 Updated def, no version needed. AK 11/6/13","administrativeNotes":"2023.8.9 Updated def for 'No Value Exists'. ak","unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3553940","version":"1","longName":"BRIDG","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"4133055","version":"1","longName":"Version 3.2","context":"NHLBI"}]},{"publicId":"6685474","version":"1","longName":"Artificial Neural Network Algorithm for BRIDG Mapping","context":"NCIP","ClassificationSchemeItems":[{"publicId":"6685476","version":"1","longName":"Training Set","context":"NCIP"}]}],"AlternateNames":[{"name":"pre_ted_who_histiocytic","type":"NMDP_FN","context":"NHLBI"},{"name":"PerformedDiagnosis:value","type":"HCT_BRIDG","context":"NHLBI"},{"name":"PreTed_prime_dis_hct_hisiocytic_disord_class","type":"NMDP_FN","context":"NHLBI"},{"name":"CPRE_ICT_hisiocytic_disord_cls","type":"NMDP_FN","context":"NHLBI"},{"name":"TDIS_HD_hisiocytic_disord_clss","type":"NMDP_FN","context":"NHLBI"}],"ReferenceDocuments":[{"name":"PQT","type":"Preferred Question Text","description":"What was the classification of the histiocytic disorder?","url":null,"context":"NHLBI"},{"name":"Specify histiocytic disorder classification","type":"Application Standard Question Text","description":"Specify histiocytic disorder classification","url":null,"context":"NHLBI"},{"name":"Specify histiocytic disorder classification","type":"Alternate Question Text","description":"Specify histiocytic disorder classification","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"DRAFT MOD","registrationStatus":"Application","id":"0F26BF38-24B5-1D4B-E063-731AD00A1C1F","latestVersionIndicator":"Yes","beginDate":"2007-10-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","changeDescription":". Added alt name/ASQT for 2400. AK 10/24/13 Updated def.  No version needed. AK 11/6/13 Added human readable def. System generated def displayed as alt def. No version needed. AK 11/17/14","administrativeNotes":"2024.1.17 Created per ticket request CADSR0003263. ak","unresolvedIssues":null,"deletedIndicator":"No"}}